西妥昔单抗治疗转移性大肠癌的经济学评价  

Economic Analysis of Cetuximab in Therapy of Metastatic Colorectal Cancer

作　　者：田泾[1] 刘正跃[1] 严萍萍[1] 王卓[1] 高申[1] 

机构地区：[1]上海长海医院,上海200433

出　　处：《药物流行病学杂志》2015年第7期421-424,共4页Chinese Journal of Pharmacoepidemiology

基　　金：国家科技支撑计划子课题(编号:.2013BAI06B04)

摘　　要：目的:对西妥昔单抗治疗转移性大肠癌(m CRC)进行经济学评价。方法:基于社会视角,采用二次文献研究和模型研究方法,根据接受化疗的转移性大肠癌患者健康状态发展规律,构建Markov模型,对比西妥昔单抗联合氟尿嘧啶为基础的方案(C+FBC)与单独使用氟尿嘧啶为基础的方案(FBC),以成本效果比(CER)、增量成本效果比(ICER)作为评价指标,并对结果进行敏感度分析。结果:以14 d为一个模型周期,在120个模型周期内,C+FBC组转移性大肠癌患者获得的质量调整生命年(QALY)为1.821年,FBC组转移性大肠癌患者获得的质量调整生命年(QALY)为0.942年,C+FBC组费用为3 430 757.5元,FBC组费用为617 064.5元。C+FBC组成本效果比为1 883 996.4,FBC组成本效果比为655 057.9,增量成本效果比为3 201 012.5。进行敏感性分析对结果没有影响。结论:单独使用氟尿嘧啶为基础的方案对于转移性大肠癌患者更具有成本效果。Objective：To evaluate the cost-effectiveness of cetuximab in therapy of metastatic colorectal cancer. Methods：The evaluation was based on social perspective. A markov model was constructed to simulate the development of the health status of patients receiving chemotherapy for metastatic colorectal cancer, comparing of fluoropyrimidine-based chemotherapy in combination with cetuximab（ C ＋ FBC） and fluoropyrimidine-based chemotherapy （FBC）. Cost-effectiveness ratio （CER） and incremental cost-effectiveness ratio （ICER） were used as the evaluation indicators in the study. Sensitivity analysis was done to make sure that the conclusion was reliable. Results：Within 120 cycles （14 days as one cycle） of the model,the quality-adjusted life year （QALY） of the C ＋ FBC group were 1. 821 years, and the FBC group were 0.942 years. It costed 3 430 757.5 Yuan for the patients of C ＋ FBC group, while the cost for patients of FBC group were 617 064.5 Yuan. The CER of C ＋ FBC group was 1 883 996.4, while the CER of FBC group was 655 057.9. The ICER was 3 201 012.5. Sensitivity analysis results showed that did not change the base case conclusions. Conclusion： The FBC had more cost efectiveness than the C ＋ FBC when was used for patients with metastatic colorectal cancer.

关 键 词：马尔可夫模型 西妥昔单抗 转移性大肠癌 经济学评价 

分 类 号：F407.7[经济管理—产业经济]